Literature DB >> 3756435

Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders.

J Malmaeus, T Akre, H O Adami, H Hagberg.   

Abstract

One hundred and sixty-seven patients subjected to splenectomy on haematological indications were studied. They were grouped into five diagnostic categories: auto-immune disorders (52 patients), Hodgkin's disease (32) lymphoproliferative malignancies (60), myeloproliferative malignancies (18) and miscellaneous (5). The total number of complications and deaths were 42 (25 per cent) and nine (5 per cent), respectively. Infections were the most common complication, occurring in 30 cases and accounting for 59 per cent of all sequelae. Patients with auto-immune disorders had a high frequency of subphrenic left-sided abscesses (5/52). Splenectomy for Hodgkin's disease was associated with a very low frequency of complications. In the 60 patients with lymphoproliferative malignancies left-sided pneumonia was common (9/60). Complications occurred in 56 per cent of the patients with myeloproliferative disorders, the associated mortality rate being 28 per cent. It is concluded that elective splenectomy in haematological diseases seems to be a safe procedure in most patients with the exception of individuals with myeloproliferative malignancies. The high operative risk in this group makes the benefit questionable. In patients with auto-immune disorders the high frequency of subphrenic abscesses indicates that prophylactic antibiotic treatment should be considered.

Entities:  

Mesh:

Year:  1986        PMID: 3756435     DOI: 10.1002/bjs.1800730915

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  12 in total

1.  Influence of splenectomy on platelet morphometry and function.

Authors:  A Wehmeier; R E Scharf; W Schneider
Journal:  Klin Wochenschr       Date:  1990-09-03

2.  Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases.

Authors:  Jan Kriz; Oliver Micke; Frank Bruns; Uwe Haverkamp; Ralph Mücke; Ulrich Schäfer; Heinrich Seegenschmiedt; Rolf-Peter Müller; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2011-03-07       Impact factor: 3.621

3.  Changing patterns in the management of splenic trauma: the impact of nonoperative management.

Authors:  H L Pachter; A A Guth; S R Hofstetter; F C Spencer
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

Review 4.  Methodologies in creating skin substitutes.

Authors:  Mathew N Nicholas; Marc G Jeschke; Saeid Amini-Nik
Journal:  Cell Mol Life Sci       Date:  2016-05-06       Impact factor: 9.261

5.  Laparoscopic splenectomy in patients with hematologic diseases.

Authors:  J L Flowers; A T Lefor; J Steers; M Heyman; S M Graham; A L Imbembo
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

6.  Laparoscopic splenectomy. The suspended pedicle technique.

Authors:  S P Dexter; I G Martin; D Alao; D R Norfolk; M J McMahon
Journal:  Surg Endosc       Date:  1996-04       Impact factor: 4.584

7.  Laparoscopic splenectomy.

Authors:  E C Poulin; C Thibault; J Mamazza
Journal:  Surg Endosc       Date:  1995-02       Impact factor: 4.584

8.  [Fatal infection after splenectomy despite reimplantation of splenic tissue].

Authors:  S Michalski; P Blankenhorn; G Lepsien; F E Lüdtke
Journal:  Klin Wochenschr       Date:  1991-05-24

9.  Splenectomy for hypersplenism caused by adult T-cell leukemia: report of a case.

Authors:  Yuichi Endo; Masayuki Ohta; Kohei Shibata; Seiichiro Kai; Kentaro Iwaki; Hiroki Uchida; Masao Ogata; Junji Ikewaki; Kenji Kashima; Seigo Kitano
Journal:  Surg Today       Date:  2008-11-28       Impact factor: 2.549

10.  Postoperative complications after splenectomy for hematologic malignancies.

Authors:  J Horowitz; J L Smith; T K Weber; M A Rodriguez-Bigas; N J Petrelli
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.